Geron Corp - GERN STOCK NEWS

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for 550,000 shares of its common stock to new employees as an inducement in their employment. The options were issued on August 18, 2021, at an exercise price of $1.25 per share, matching the stock's closing price on that date. The options vest over four years, with an initial vesting of 12.5% after six months. Geron is focused on developing the telomerase inhibitor, imetelstat, and is conducting two Phase 3 clinical trials in related hematologic cancers.

Geron Corporation (Nasdaq: GERN) announced updates on its IMerge Phase 3 trial in lower risk MDS and reported second quarter financial results. As of June 30, 2021, the company has $239.1 million in cash and securities, sufficient to fund operations through Q1 2023. Enrollment in the IMerge trial reached 91%, with full enrollment expected by Q4 2021, and top-line results anticipated by Q1 2023, accelerated by three months. Furthermore, Geron plans to host an investor event in November 2021 to discuss imetelstat's potential and development pipeline.

Geron Corporation (Nasdaq: GERN) will release its Q2 2021 financial results after market close on August 16, 2021. The results will be detailed in a press release available on the company’s website. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent events. Key highlights include ongoing Phase 3 clinical trials for imetelstat in hematologic malignancies. A live webcast will also be accessible on the company's site, with an archive available for 30 days.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 130,000 shares of its common stock to new employees, effective July 21, 2021. The exercise price is $1.33 per share, matching the closing price on the grant date. The options will vest over four years, with 12.5% vesting after six months and the remainder in equal monthly installments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the 2018 Inducement Award Plan. Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic diseases with ongoing Phase 3 trials.

Geron Corporation (Nasdaq: GERN) announced the publication of data from the IMbark Phase 2 trial in the Journal of Clinical Oncology, showcasing clinical benefits of imetelstat in treating relapsed or refractory myelofibrosis (MF). Key findings include improved symptom response rates and overall survival in patients with high disease burden. The upcoming IMpactMF Phase 3 trial will further assess imetelstat's efficacy against standard therapies, targeting 320 patients. Imetelstat, a first-in-class telomerase inhibitor, has received Fast Track designation from the FDA for MF and related conditions.

Geron Corporation (Nasdaq: GERN) announced new clinical data for imetelstat, a first-in-class telomerase inhibitor, presented at EHA2021 Virtual Congress. The data support imetelstat's mechanism targeting malignant stem and progenitor cells, emphasizing its potential to transform treatment for myelodysplastic syndromes (MDS) and myelofibrosis (MF). Results from the IMerge Phase 2 trial indicate durable transfusion independence, while safety analyses show manageable adverse events. Geron is conducting two Phase 3 trials for imetelstat, which has received Fast Track designation from the FDA.

Geron Corporation (Nasdaq: GERN) announced two poster presentations at the EHA Annual Congress regarding clinical data for imetelstat, a telomerase inhibitor. The posters, available on June 11, 2021, showcase findings from the Phase 2 IMbark and IMerge trials, highlighting imetelstat's efficacy in treating lower risk MDS and MF patients. Notably, it demonstrated clinical benefit across molecular subtypes and an acceptable safety profile. Geron is advancing imetelstat for regulatory approval, having received Fast Track designation from the FDA.

Geron Corporation (Nasdaq: GERN) reported financial results for Q1 2021, posting a net loss of $27.8 million, or $0.09 per share, compared to a loss of $16.4 million, or $0.08 per share, in Q1 2020. Revenues increased to $137,000 from $52,000 year-over-year. The company maintains $244.7 million in cash, expected to fund operations until 2022. Geron is progressing in two Phase 3 clinical trials for imetelstat, with 75% enrollment in MDS and the first patient dosed in MF. The company aims for a commercial launch of imetelstat in 2023, with ongoing preparations for regulatory filings.

Geron Corporation (Nasdaq: GERN) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss results and recent developments. Investors can access the press release and the live webcast on the company's website. Geron is advancing a first-in-class telomerase inhibitor, imetelstat, targeting hematologic malignancies and is currently conducting two Phase 3 trials: IMerge and IMpactMF. For further information, visit www.geron.com.